 |
Previous Article | Next Article 
The Journal of Neuroscience, 2002, 22:RC202:1-5
RAPID COMMUNICATION
Dysregulation of Ascorbate Release in the Striatum of Behaving
Mice Expressing the Huntington's Disease Gene
George V.
Rebec,
Scott J.
Barton, and
Michelle D.
Ennis
Program in Neural Science, Department of Psychology, Indiana
University, Bloomington, Indiana 47405-7007
 |
ABSTRACT |
The extracellular fluid of the striatum contains a high level of
ascorbate, an antioxidant vitamin known to play a key role in
behavioral activation. We assessed the extracellular dynamics of
ascorbate in R6/2 mice engineered to express the gene for Huntington's disease (HD), an autosomal dominant condition characterized by the loss
of striatal neurons. Slow-scan voltammetry was used to measure striatal
ascorbate during anesthesia and subsequent behavioral recovery.
Although both the HD mice and their littermate controls had comparable
ascorbate levels during anesthesia, the gradual return of behavioral
activation over the next 120 min led to dramatically different
ascorbate responses: a progressive increase in controls and a 25-50%
decline in HD mice. In contrast, 3,4-dihydroxyphenylacetic acid, a major dopamine metabolite, showed no group differences. Behaviorally, HD mice were less active overall than controls and showed
a relatively restricted range of spontaneous movements. Both the
ascorbate and behavioral deficits were evident in 6-week-old HD mice
and persisted in all subsequent test sessions through 10 weeks of age.
Collectively, although these results are consistent with inadequate
antioxidant protection in the HD striatum, they indicate that the
ascorbate deficit is confined to periods of behavioral activation.
Key words:
ascorbate; basal ganglia; dopamine; glutamate; Huntington's disease; motor control; striatum; voltammetry
 |
INTRODUCTION |
Huntington's
disease (HD), a progressive neurodegenerative disorder of the striatum,
is characterized by striking behavioral changes, most notably deficits
in cognition and motor control (Vonsattel and DiFiglia, 1998 ). Although
HD is caused by an expanded polyglutamine repeat within the coding
region of the HD gene (Huntington's Disease Collaborative Research
Group, 1993 ), pharmacological and other efforts to reverse HD symptoms
have been largely ineffective. Such outcomes have led to the
development of transgenic mouse models that mimic the progressive
behavioral and neurological phenotype of HD to provide a basis for
testing new therapies. One of these models, the R6/2 line, develops
many of the motor-control deficits that are characteristic of HD
(Carter et al., 1999 ). In this report, we evaluated the behavioral
phenotype of these mice and assessed potential deficits in ascorbate,
the physiological form of vitamin C found throughout the extracellular
fluid of the striatum (Basse-Tomusk and Rebec, 1991 ).
Although the precise role of ascorbate in striatal function is unclear,
increasing evidence indicates that it is important to monitor the HD
striatum for a possible ascorbate imbalance. At the cellular level,
ascorbate offers antioxidant protection against highly reactive oxygen
species (Rice, 2000 ). The accumulation of these substances leads to
oxidative stress and excitotoxicity, both of which have been implicated
in HD pathogenesis (Browne et al., 1999 ; Sayre et al., 2001 ). It also
is interesting that a loss of striatal ascorbate impairs motor behavior
(Rebec and Wang, 2001 ), a prototypical feature of HD (Penney and Young,
1998 ).
To examine a possible ascorbate deficit in the HD striatum, we used
slow-scan voltammetry to measure extracellular ascorbate in both R6/2
mice expressing exon 1 of the human HD gene and their littermate
controls. Because ascorbate release is linked to behavioral activation
(Rebec and Pierce, 1994 ), we monitored the change in striatal ascorbate
release as animals recovered from general anesthesia. Our recordings
also provided data on 3,4-dihydroxyphenylacetic acid (DOPAC), a
major dopamine metabolite.
 |
MATERIALS AND METHODS |
Animals. R6/2 mice (B6CBA-TgN[HDexon1]62Gpb) were
obtained from The Jackson Laboratory (Bar Harbor, ME) at 5 weeks of
age. Data were collected from male hemizygous HD mice and littermate controls. All mice were housed individually in the departmental animal
colony under standard conditions (12 hr light/dark cycle with lights on
at 7:30 A.M.) with access to food and water ad libitum. Both
the housing and experimental use of the animals followed National
Institutes of Health guidelines and were approved by the Institutional
Animal Care and Use Committee.
Preparation for voltammetric recording. Shortly after
arrival in the colony, animals were anesthetized with chloropent (0.4 ml/100 gm, i.p.) and mounted in a stereotaxic frame. The skull was
exposed and bilateral holes were drilled over the striatum (0.5 mm
anterior and 2.0 mm lateral to bregma). A plastic hub was secured over
each hole at a 5° angle to allow for adjacent placement of both
working and reference electrodes (Rebec and Wang, 2000 ). Each hub was
sealed with a plastic cap, and the animals were returned to the colony
for at least 4 d of recovery.
Voltammetry. A glass-insulated carbon fiber (10 µm
diameter) served as the working electrode for voltammetric recording.
The active surface area extended beyond the glass by ~150 µm. The electrode was electrochemically pretreated, as in previous work (Pierce
and Rebec, 1993 ), to separate the oxidation signals for ascorbate,
DOPAC, and other easily oxidized endogenous compounds (Gonon et al.,
1981b ). Ample evidence has confirmed the identity of the ascorbate and
DOPAC signals in rodent striatum (Rebec and Wang, 2001 ; Kamata et al.,
1986 ), and applications of exogenous ascorbate have confirmed the
ascorbate signal in mice (Rebec and Barton, 2001 ). Generation of
waveforms for staircase voltammetry and storage of sampled current was
performed using a computer interfaced to a locally constructed
potentiostat operating in two-electrode mode. A potential was applied
in 6 mV steps from 200 to +600 mV versus reference to ensure
ascorbate and DOPAC oxidation. The scan rate was set at 20 mV/sec;
scans were obtained at 60 sec intervals.
On the recording day, the working electrode was first tested in
citrate-phosphate buffer containing 100 µM ascorbate and
20 µM DOPAC to ensure adequate sensitivity and peak
separation. Both the working electrode and a Ag/AgCl reference
electrode were fitted into separate miniaturized microdrives (total
weight of <2 gm) designed to mate with the head-mounted hubs (Rebec
and Wang, 2000 ). To install the microdrives, we anesthetized each mouse
(half the anesthetic dose for surgery) and removed the cap over each
hub. The working electrode was lowered manually into the left or right striatum (~3.2 mm ventral to skull surface), whereas the reference electrode was positioned in the contralateral hub and lowered onto the
brain surface. A lightweight, shielded cable attached to each
microdrive was connected to the potentiostat via an electric swivel to
permit complete freedom of movement. Each animal was placed in a
circular, glass arena (15 cm diameter) housed inside a
sound-attenuating cubicle for recording. After 10-20 min to allow the
voltammetric signal to stabilize, scans were obtained for the next 2.5 hr, which included the initial period of anesthesia (30-60 min) and
subsequent behavioral activation. After completion of the recording
session, most electrodes were removed and tested for sensitivity in a
postcalibration step, but some were used to mark the recording site
(see below).
In most cases, we were able to record from the opposite striatum 2-3
weeks later. For the second recording session, new working and
reference electrodes were prepared, and their left-right placement was
reversed. This strategy allowed us to record twice from undisturbed striatal tissue in the same animal. The second session followed the
same protocol as the first (i.e., recording during and after a period
of light anesthesia).
Ethological assessment. All behavioral tests were run at
least 1 d before or 2 d after voltammetric recording. No
behavioral data were obtained after an electrode-marking lesion. Mice
were individually placed in an open-field arena (45 × 26 cm) with
clear, Plexiglas walls (20 cm) in an isolated observation room equipped with videotaping facilities. A wire-mesh cylinder for climbing (7 cm
tall and 4 cm diameter) was placed near the center of the arena along
with a rubber ball (~2 cm diameter); inert wood shavings covered the
floor. Each mouse remained in the arena for 15 min of videotaping and
was then returned to the home cage. Testing was performed weekly for at
least 5 weeks. All sessions occurred between 10:30 A.M. and 12:30
P.M.
Videotapes were analyzed by an independent observer who recorded 10 operationally defined behavioral categories: climbing the cylinder,
crawling along the rim of the arena, digging in or pushing the bedding,
grooming (either forepaw or hindpaw), jumping, forward locomotion,
pushing the ball, rearing, sniffing (head or whisker movement), and
quiet rest. An ethogram was compiled in which the total number of
behaviors and the percentage of time spent exhibiting each behavior
were noted for each session.
Histology. To verify electrode placement for voltammetry,
some animals were deeply anesthetized and current was passed through the working electrode to mark the recording site. Subsequent
transcardial perfusion with formosaline was followed by histological
analysis to confirm recording location.
Data analysis. For voltammetry, ascorbate and DOPAC peak
heights were measured at the apex in millimeters. Estimates of
mean ± SEM concentration were based on postcalibration data as
described previously (Basse-Tomusk and Rebec, 1991 ). Changes in
extracellular ascorbate and DOPAC levels during wakefulness were
expressed as percentage of anesthesia baseline. Ethological data were
analyzed for the total number of behavioral items as well as age
differences between HD and control mice. Statistical comparisons were
made by ANOVA or Student's t tests for paired samples.
 |
RESULTS |
Both groups of animals gained weight over the course of the
experiment, typically progressing from 20 to 25 gm, arguing against a
HD-related nutritional deficit. A total of 13 HD and 15 control mice
were used for voltammetry, and most (8 HD mice and 11 control mice)
were included in two recording sessions. The first session occurred
when animals were between 6 and 8 weeks of age, and the second session
occurred 2-3 weeks later. Subsets of these animals (7 HD mice and 7 control mice) were run in weekly ethological assessments of behavior.
Voltammetry
All voltammetric scans obtained from all mice in all sessions
revealed distinct oxidation peaks between 70 and 50 mV and between
+80 and +100 mV versus reference. Thorough characterization of these
peaks in vivo (Gonon et al., 1981a ) as well as in
vitro testing of each electrode indicated that these peaks
represented ascorbate and DOPAC, respectively. Sample scans, which also
depict a third peak thought to represent serotonin, uric acid, and
other oxidizables, are shown in Figure
1A.

View larger version (18K):
[in this window]
[in a new window]
|
Figure 1.
Voltammetric data from the striatum.
A, Representative voltammograms obtained from a
6-week-old HD mouse during anesthesia (solid line) and
after behavioral recovery ~120 min later (asterisks).
Note that the ascorbate (AA) peak, which occurs between
70 and 50 mV, shows a behavior-related decline. No such change
occurs in the DOPAC peak (between +70 and +90 mV). Several oxidized
species are represented in a third, unanalyzed peak (more than +200
mV). B, Time course of the change in magnitude of the ascorbate peak
recorded during the first recording session for one control and one HD
mouse (see above). Both animals are 6 weeks of age. Data are
based on individual scans obtained at 5 min intervals and are presented
as percentage of change from the first scan obtained 15 min after
injection of anesthetic (time 0) when the animals are completely
inactive. In both cases, signs of behavioral activation (crawling, head
movement, twitching, etc.) begin between time 50 and time 60. C, Mean ± SEM percentage of change in magnitude
from anesthesia baseline of the ascorbate and DOPAC signals for all HD
and all control mice during postanesthesia behavioral activity (see
above). Data, which were averaged across all recording sessions
in all animals, are plotted for the last 5 min of each session, when
behavioral activation was greatest. The HD ascorbate response is
significantly different from the control response
(p < 0.01); there is no difference in the
DOPAC response.
|
|
At the beginning of each recording session, all mice were anesthetized
to allow placement of the working electrode in the striatum. Under
these conditions, there were no group differences in estimated
concentrations of either ascorbate or DOPAC. No age differences
emerged, and the data are summarized for all recordings in control and
HD mice in Table 1.
View this table:
[in this window]
[in a new window]
|
Table 1.
Estimated mean ± SEM extracellular concentration of
ascorbate and DOPAC in the striatum during anesthesia baseline
|
|
After 30-60 min, both groups of animals awoke and showed increased
behavioral activation. In HD mice, this behavioral change was
accompanied by a progressive decline in the amplitude of the ascorbate
signal, in some cases by up to 50% (Fig. 1A).
Controls, in contrast, showed an ascorbate increase as they became
behaviorally active. The time course of these opposing ascorbate
changes is shown in Figure 1B for one animal in each
group at 6 weeks of age. Note the beginning of the sharp divergence in
the ascorbate response at 60 min, when behavioral activation is
imminent. HD mice that emerged from anesthesia sooner showed a similar
ascorbate decline but a correspondingly sooner onset. Group data on the ascorbate and DOPAC responses from the last recording of each session
when animals were most behaviorally active are presented in Figure
1C. The ascorbate difference between HD mice and controls is
statistically significant (p < 0.01). Note also
that the DOPAC response, although variable, is comparable in both groups.
The ascorbate decline in the striatum of awake HD mice persisted across
all weeks of testing. No differences emerged between the first or the
second recording session. Controls showed variable increases with age.
Ethological assessment
All mice were active when placed in a relatively natural
environment with many behavioral choices, but clear group differences emerged. As shown in Figure 2, HD mice
allocated a significantly smaller percentage of their behavioral
responses to rearing, digging, sniffing, and climbing than controls. In
fact, only two of seven HD mice showed climbing behavior, but this
behavior was observed for these two mice in every session, even as late
as 10 weeks. In contrast, all controls climbed in every session. Two
behaviors (crawling on the rim of the cage and pushing the ball) were
never expressed by HD mice and were rare even in controls, accounting for <2% of all responses. The only behavior never expressed by controls, however, was quiet rest, which accounted for ~5% of behavior in HD mice. Although HD mice spent more time grooming and
locomoting than controls, this difference primarily reflected a
stereotyped flick of the hindpaw toward the ipsilateral ear, a behavior
unique to these animals (Carter et al., 1999 ).

View larger version (36K):
[in this window]
[in a new window]
|
Figure 2.
Frequency of expression of key behavioral
categories for control and HD mice across all videotaping sessions.
Data are presented as mean ± SEM percentage of total. Note that
in HD mice behavior was primarily confined to locomotion and grooming,
with ample periods of rest. HD and control mice are significantly
different for all behaviors except jumping.
|
|
Of the 10 distinct items of behavior recorded in each ethological
session, control mice (n = 7) at all ages displayed all items at least once, compiling a mean ± SEM of 8.2 ± 0.21 items per session, whereas the mean ± SEM of 6.5 ± 0.24 items in HD mice (n = 7) was significantly lower
(p < 0.001). Approximately the same degree of
difference was evident at each of the ages tested.
HD mice consistently engaged in less behavior overall. The mean ± SEM total behavior count per session analyzed across all sessions was
689 ± 22 in controls but only 240 ± 21 in HD mice (p < 0.001). Data for weekly sessions showed
diverging linear trends with a progressive increase in controls and a
progressive decline in HD mice. Controls, for example, scored 666 ± 47 and 731 ± 124 counts/session at 6 and 10 weeks of age,
respectively, whereas HD mice went from 280 ± 50 to 160 ± 30 counts/session over this same period. An overall ANOVA on weekly
session data revealed a significant difference
(p < 0.001). Subsequent post hoc
analysis revealed a significant difference at each week
(p < 0.01).
 |
DISCUSSION |
Our results support the emerging concept of striatal ascorbate
release during behavioral activation and indicate a disruption of this
process in the striatum of HD mice. In fact, HD mice, which display a
wide array of motor deficits, show a pronounced and sustained loss of
ascorbate in striatal extracellular fluid that appears only during
periods of behavioral activation. Thus, the problem in these animals is
not an ascorbate deficit per se, but rather a failure to maintain
adequate extracellular levels under behaviorally active conditions.
A low level of striatal ascorbate is consistent with inadequate
antioxidant protection as a basis for HD pathogenesis (Coyle and
Puttfarcken, 1993 ). In fact, immunohistochemical studies of HD brain
show increased levels of nitrotyrosine and malondialdehyde adducts,
both of which suggest oxidative damage (Browne et al., 1999 ). The HD
brain also shows elevated levels of the hydroxy radical, a cellular
marker of oxidative stress (Sayre et al., 2001 ). It is not clear,
however, whether oxidative mechanisms are a cause or a consequence of
HD (Alam et al., 2000 ; Perez-Severiano et al., 2000 ). The same
uncertainty applies to the loss of ascorbate in HD mice, but if the
loss indicates increased vulnerability to oxidative stress, then our
results suggest that the vulnerability is confined to periods of
behavioral activity.
Striatal ascorbate release depends on the activation of
glutamate-releasing afferents from the cerebral cortex (Basse-Tomusk and Rebec, 1990 ), most likely involving heteroexchange with glutamate during glutamate uptake (O'Neill, 1995 ). Thus, a change in ascorbate release reflects a change in glutamate transmission (Fillenz et al.,
1986 ). Although some cortical damage occurs in HD (Vonsattel and
DiFiglia, 1998 ), corticostriatal degeneration cannot explain an
ascorbate deficit that depends on behavioral state. It seems more
likely that HD impairs the normal operation of corticostriatal neurons.
Consistent with this view, HD patients show context-dependent deficits
in striatal function that suggest abnormally low corticostriatal activity (Lawrence et al., 2000 ). Under these conditions, ascorbate release would also be low. Alternatively, however, low ascorbate may
result not from a decline in glutamate transmission, but, if the
heteroexchange model is correct, from a failure of glutamate uptake. In
this case, because ascorbate normally protects against glutamate-evoked
oxidative damage (Rice, 2000 ), low ascorbate in the face of high
glutamate could trigger the degeneration characteristic of HD (Beal,
1998 ; Levine et al., 1999 ; Meade et al., 2000 ; Perez-Severiano et al.,
2000 ). In either case, our results suggest a need for further
assessment of glutamate function in HD striatum.
Although we found DOPAC to be relatively normal in HD mice, this
metabolite primarily represents intracellular dopamine metabolism (Kuczenski and Segal, 1989 ). Thus, we cannot rule out a postsynaptic abnormality. In fact, HD mice show a deficiency of dopamine-regulated phosphoprotein markers as well as deficits in dopamine-regulated ion
channels and the D1 dopamine receptor signaling cascade (Bibb et al.,
2000 ). Therefore, if a dopamine malfunction plays a role in HD
pathogenesis, postsynaptic rather than presynaptic events are likely to
be involved.
Although systemic injections of ascorbate can either enhance or
suppress motor activity depending on dose (Rebec and Pierce, 1994 ), the
release of endogenous ascorbate in the striatum is correlated with
behavioral activation (O'Neill and Fillenz, 1985 ; Boutelle et al.,
1989 ; Mueller, 1989 ; Pierce and Rebec, 1990 ). We saw a similar
relationship in our control mice. In contrast, our HD mice showed
behavioral deficits similar to those reported for rats treated with
intrastriatal infusions of ascorbate oxidase, which deplete
extracellular ascorbate by at least 50% (Rebec and Wang, 2001 ).
Like HD mice, these rats become hypoactive and fail to interact with
environmental stimuli. Although HD mice spent more time than controls
in locomotion, this appeared to be a default response to the decline in
other behaviors rather than a preference for forward movement. Overall,
HD mice engaged in fewer categories of behavior and spent more time
resting than controls. In an interesting parallel with evidence that
environmental enrichment delays the onset of motor symptoms in HD mice
(van Dellen et al., 2000 ), our two HD mice that climbed at 6 weeks of
age maintained this behavior throughout testing. Early expression of a
behavior seems to be crucial for its maintenance, because our other HD
mice never showed a climbing response at any age tested.
In sum, our results both extend the behavioral phenotype of R6/2 mice
and identify a profound deficit in the control of extracellular ascorbate in the striatum. Although the behavioral data can be useful
in developing sensitive assays for testing new therapeutic strategies,
the loss of striatal ascorbate points to neuronal deficits that may
underlie the disease process, including abnormalities in striatal
glutamate transmission. It is also significant that the
ascorbate deficit emerges when HD mice are behaviorally active. Although brain ascorbate has not been assessed in HD patients, our
results, given the comparable distribution of brain ascorbate in
rodents (Milby et al., 1982 ) and humans (Mefford et al., 1981 ), suggest
a deficiency in the regulation of striatal ascorbate that may hold the
key to identifying the mechanism underlying HD.
 |
FOOTNOTES |
Received Oct. 1, 2001; revised Nov. 5, 2001; accepted Nov. 8, 2001.
This research was supported by the Hereditary Disease Foundation and by
the National Institute of Neurological Disorders and Stroke Grant NS
35663. We also acknowledge the technical contributions of Paul Langley
and the editorial assistance of Faye Caylor.
Correspondence should be addressed to George V. Rebec, Psychology
Building, 1101 East Tenth Street, Bloomington, IN 47405-7007. E-mail:
rebec{at}indiana.edu.
This article is published in
The Journal of Neuroscience, Rapid Communications Section,
which publishes brief, peer-reviewed papers online, not in print. Rapid
Communications are posted online approximately one month earlier than
they would appear if printed. They are listed in the Table of Contents
of the next open issue of JNeurosci. Cite this article as:
JNeurosci, 2002, 22:RC202 (1-5). The
publication date is the date of posting online at
www.jneurosci.org.
 |
REFERENCES |
-
Alam ZI,
Halliwell B,
Jenner P
(2000)
No evidence for increased oxidative damage to lipids, proteins, or DNA in Huntington's disease.
J Neurochem
75:840-846.
-
Basse-Tomusk A,
Rebec GV
(1990)
Corticostriatal and thalamic regulation of amphetamine-induced ascorbate release in the neostriatum.
Pharmacol Biochem Behav
35:55-60.
-
Basse-Tomusk A,
Rebec GV
(1991)
Regional distribution of ascorbate and 3,4-dihydroxyphenylacetic acid (DOPAC) in rat neostriatum.
Brain Res
538:29-35.
-
Beal MF
(1998)
Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis.
Ann Neurol
44:S110-S114.
-
Bibb JA,
Yan Z,
Svenningsson P,
Snyder GL,
Pieribone VA,
Horiuchi A,
Nairn AC,
Messer A,
Greengard P
(2000)
Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice.
Proc Natl Acad Sci USA
97:6809-6814.
-
Boutelle MG,
Svensson L,
Fillenz M
(1989)
Rapid changes in striatal ascorbate in response to tail-pinch monitored by constant potential voltammetry.
Neuroscience
30:11-17.
-
Browne SE,
Ferrante RJ,
Beal MF
(1999)
Oxidative stress in Huntington's disease.
Brain Pathol
9:147-163.
-
Carter RJ,
Lione LA,
Humby T,
Mangiarini L,
Mahal A,
Bates GP,
Dunnett SB,
Morton AJ
(1999)
Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation.
J Neurosci
19:3248-3257.
-
Coyle JT,
Puttfarcken P
(1993)
Oxidative stress, glutamate, and neurodegenerative disorders.
Science
262:689-695.
-
Fillenz M,
O'Neill RD,
Grunewald RA
(1986)
Changes in extracellular brain ascorbate concentration as an index of excitatory amino acid release.
In: Monitoring neurotransmitter release during behaviour (Joseph MH,
Fillenz M,
MacDonald IA,
Marsden CA,
eds), pp 144-163. Chichester, UK: Ellis Norwood.
-
Gonon F,
Buda M,
Cespuglio R,
Jouvet M,
Pujol JF
(1981a)
Voltammetry in the striatum of chronic freely moving rats: detection of catechols and ascorbic acid.
Brain Res
223:69-80.
-
Gonon FG,
Fombarlet CM,
Buda MJ,
Pujol JF
(1981b)
Electrochemical treatment of pyrolytic carbon fiber electrodes.
Anal Chem
53:1386-1389.
-
Huntington's Disease Collaborative Research Group
(1993)
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.
Cell
72:971-983.
-
Kamata K,
Wilson RL,
Alloway KD,
Rebec GV
(1986)
Multiple amphetamine injections reduce the release of ascorbic acid in the neostriatum of the rat.
Brain Res
362:331-338.
-
Kuczenski R,
Segal D
(1989)
Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis.
J Neurosci
9:2051-2065.
-
Lawrence AD,
Watkins LHA,
Sahakian BJ,
Hodges JR,
Robbins TW
(2000)
Visual object and visuospatial cognition in Huntington's disease: implications for information processing in corticostriatal circuits.
Brain
123:1349-1364.
-
Levine MS,
Klapstein GJ,
Koppel A,
Gruen E,
Cepeda C,
Vargas ME,
Jokel ES,
Carpenter EM,
Zanjani H,
Hurst RS,
Efstratiadis A,
Zeitlin S,
Chesselet MF
(1999)
Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease.
J Neurosci Res
58:515-532.
-
Meade CA,
Figueredo-Cardenas G,
Fusco F,
Nowak TS,
Pulsinelli WA,
Reiner A
(2000)
Transient global ischemia in rats yields striatal projection neuron and interneuron loss resembling that in Huntington's disease.
Exp Neurol
166:307-323.
-
Mefford IN,
Oke AF,
Adams RN
(1981)
Regional distribution of ascorbate in human brain.
Brain Res
212:223-226.
-
Milby K,
Oke A,
Adams RN
(1982)
Detailed mapping of ascorbate distribution in rat brain.
Neurosci Lett
28:169-174.
-
Mueller K
(1989)
Repeated administration of high doses of amphetamine increases release of ascorbic acid in caudate but not nucleus accumbens.
Brain Res
494:30-35.
-
O'Neill R
(1995)
The measurement of brain ascorbate in vivo and its link with excitatory amino acid neurotransmission.
In: Neuromethods: voltammetric methods in brain systems (Boulton A,
Baker G,
Adams RN,
eds), pp 221-268. Clifton, NJ: Humana.
-
O'Neill RD,
Fillenz M
(1985)
Circadian changes in extracellular ascorbate in rat cortex, accumbens, striatum, and hippocampus: correlations with motor activity.
Neurosci Lett
60:331-336.
-
Penney Jr JB,
Young AB
(1998)
Huntington's disease.
In: Parkinson's disease and movement disorders (Jankovic J,
Tolosa E,
eds), pp 341-355. Baltimore: Lippincott Williams & Wilkins.
-
Perez-Severiano F,
Rios C,
Segovia J
(2000)
Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington's disease.
Brain Res
862:234-237.
-
Pierce RC,
Rebec GV
(1990)
Stimulation of both D1 and D2 receptors increases behavioral activation and ascorbate release in the neostriatum of freely moving rats.
Eur J Pharmacol
191:295-302.
-
Pierce RC,
Rebec GV
(1993)
Intraneostriatal administration of glutamate antagonists increases behavioral activation and decreases neostriatal ascorbate via non-dopaminergic mechanisms.
J Neurosci
13:4272-4280.
-
Rebec GV,
Barton SJ
(2001)
Daily ascorbate treatment reverses the ascorbate deficit in the striatum of behaving mice expressing the Huntington's disease (HD) gene.
Soc Neurosci Abstr
27:292.19.
-
Rebec GV,
Pierce RC
(1994)
A vitamin as neuromodulator: ascorbate release in the extracellular fluid of the brain regulates dopaminergic and glutamatergic transmission.
Prog Neurobiol
43:537-565.
-
Rebec GV, Wang Z (2000) Microtechnology for monitoring
real-time electrical and chemical events at the neuronal level in
freely behaving animals. Proceedings of the Institute of Electrical and
Electronics Engineers-Engineering in Medicine and Biology
Society Asia-Pacific Conference on Biomedical Engineering,
Hangzou, China, September. 2:511-512.
-
Rebec GV,
Wang Z
(2001)
Behavioral activation in rats requires endogenous ascorbate release in striatum.
J Neurosci
21:668-675.
-
Rice ME
(2000)
Ascorbate regulation and its neuroprotective role in the brain.
Trends Neurosci
23:209-216.
-
Sayre LM,
Smith MA,
Perry G
(2001)
Chemistry and biochemistry of oxidative stress in neurodegenerative disease.
Curr Med Chem
8:721-738.
-
van Dellen A,
Welch J,
Dixon RM,
Cordery P,
York D,
Styles P,
Blakemore C,
Hannan AJ
(2000)
N-acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice.
NeuroReport
11:3751-3757.
-
Vonsattel JP,
DiFiglia M
(1998)
Huntington disease.
J Neuropathol Exp Neurol
57:369-384.
Copyright © Society for Neuroscience 0270-6474//$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
A. G. Walker, B. R. Miller, J. N. Fritsch, S. J. Barton, and G. V. Rebec
Altered Information Processing in the Prefrontal Cortex of Huntington's Disease Mouse Models
J. Neurosci.,
September 3, 2008;
28(36):
8973 - 8982.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Cepeda, R. S. Hurst, C. R. Calvert, E. Hernandez-Echeagaray, O. K. Nguyen, E. Jocoy, L. J. Christian, M. A. Ariano, and M. S. Levine
Transient and Progressive Electrophysiological Alterations in the Corticostriatal Pathway in a Mouse Model of Huntington's Disease
J. Neurosci.,
February 1, 2003;
23(3):
961 - 969.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|